Drug Profile
Research programme: xanthine oxidase inhibitors - BTG/King's College London
Alternative Names: Xanthine oxidase inhibitors research programme - BTG/King's College LondonLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer BTG; Nonindustrial source
- Class
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Adult respiratory distress syndrome; Neurological disorders; Shock
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 18 Apr 2002 No development reported - Preclinical for Adult respiratory distress syndrome in United Kingdom (unspecified route)
- 18 Apr 2002 No development reported - Preclinical for Neurological disorders in United Kingdom (unspecified route)